Galera Therapeutics to cut 70% of staff in wake of rejection for radiotherapy complication treatment
Galera Therapeutics is chopping 70% of its staff in the wake of a stinging FDA rejection for its experimental treatment for a radiotherapy complication that causes difficulties eating and drinking.
The FDA late Wednesday rejected Galera’s avasopasem manganese, or avasopasem, for the treatment of head and neck cancer patients with radiotherapy-induced severe oral mucositis (SOM), which can occur after receiving radiation and sometimes requires patients to be on feeding tubes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.